Nasasinutab (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride, the active ingredient in Nasasinutab, is an imidazoline nasal decongestant presented as a nasal spray for intranasal use. It reduces nasal congestion associated with the common cold, sinusitis, and allergic rhinitis in adults and children.

GNH USA supplies Nasasinutab as a licensed, GDP‑compliant international pharmaceutical product to hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides regulatory documentation, batch release certificates, and cold‑chain logistics where required. GNH USA also offers technical support and post‑marketing surveillance to ensure safe use across diverse markets.

Xylometazoline Hydrochloride is used to relieve nasal congestion by acting on the upper‑respiratory tract.

Common cold: provides rapid relief of nasal blockage, allowing easier breathing and reduced feeling of fullness in the nasal passages. Sinusitis: decreases mucosal edema in the nasal passages, facilitating sinus drainage and reducing pressure associated with acute or chronic sinus inflammation. Allergic rhinitis: mitigates congestion caused by allergen‑induced inflammation, helping to restore normal nasal airflow during seasonal or perennial allergic episodes.

Xylometazoline Hydrochloride may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation - Sneezing - Dryness of the nasal mucosa - Headache

Serious or Rare Side Effects: - Rebound nasal congestion (rhinitis medicamentosa) with prolonged use - Hypertension or increased heart rate in susceptible individuals - Severe allergic reaction such as angioedema or anaphylaxis (rare)

When using Nasasinutab, several precautions should be observed to ensure safe and effective treatment.

Duration of use: limit to no more than three consecutive days to avoid rebound congestion. Underlying conditions: avoid in patients with severe hypertension or coronary artery disease without medical advice. Pregnancy and lactation: safety has not been established; use only if clearly needed and prescribed. Pediatric use: consult a healthcare professional before administering to children under six years of age. Drug interactions: inform the prescriber of concurrent use of monoamine oxidase inhibitors or other vasoconstrictors. Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Xylometazoline Hydrochloride can interact with certain systemic medications and other nasal agents.

Major Interactions (Avoid): - Concurrent use with other topical nasal decongestants: may increase risk of severe vasoconstriction and rebound congestion. - MAO inhibitors: can potentiate hypertensive effects when combined with alpha‑adrenergic agonists.

Moderate Interactions (Monitor Closely): - Oral antihypertensive agents (beta‑blockers, ACE inhibitors): may reduce their blood‑pressure‑lowering effect. - Sympathomimetic drugs (e.g., pseudoephedrine): additive vasoconstrictive action may raise blood pressure. - Nasal corticosteroids: generally safe but monitor for increased nasal irritation.